Skip to content
AwardedSpainGoods€224,059,795

Suministro de medicamentos de uso humano que contiene los principios activos siguientes: alpelisib, asciminib, basiliximab, brolucizumab, canakinumab, capmatinib, ceritinib, dabrafenib, midostaurina, ofatumumba, ribociclib, ruxolitinib, secukinumab, siponimod y trametinib, con destino a los centros del ámbito de la sanidad pública valenciana

Published
Published 12 March 2025

Overview

uministro de medicamentos de uso humano que contiene los principios activos siguientes: alpelisib, asciminib, basiliximab, brolucizumab, canakinumab, capmatinib, ceritinib, dabrafenib, midostaurina, ofatumumba, ribociclib, ruxolitinib, secukinumab, siponimod y trametinib, con destino a los centros del ámbito de la sanidad pública valenciana

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€224,059,795
Procedure
Direct
Published
12 March 2025
Classification (CPV)
Antineoplastic agentsImmunosuppressive agentsOphthalmologicals

Award outcome

Awarded value
€0
Award date
6 March 2026
Winner
  • NOVARTIS FARMACEUTICA, S.A.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    7 May 2026

  2. Contract Award Notice

    10 December 2025

  3. Contract Notice

    12 March 2025

Contracting authority

  • Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad

    Procuring entity

    Valencia, Spain

    ID_PLATAFORMA: 20897030133463

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Suministro de medicamentos de uso humano que contiene los principios activos siguientes: alpelisib, asciminib, basiliximab, brolucizumab, canakinumab, capmatinib, ceritinib, dabrafenib, midostaurina, ofatumumba, ribociclib, ruxolitinib, secukinumab, siponimod y trametinib, con destino a los centros del ámbito de la sanidad pública valenciana — won by NOVARTIS FARMACEUTICA, S.A. — Skim